IGHE and allergic asthma: Omalizumab is a humanized mAb that blocks the interaction between IgE and high-affinity receptor FcεRI on inflammatory cells; it is approved for the treatment of patients with persistent severe allergic asthma, high levels of blood IgE, and at least a sensitization to a perennial allergen [63].